Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer.

Literature DB >> 22580638

Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer.

Emmanuel S Antonarakis¹.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2012 PMID： 22580638 PMCID： PMC3720070 DOI： 10.1038/aja.2012.45

Source DB: PubMed Journal: Asian J Androl ISSN： 1008-682X Impact factor: 3.285

× No keyword cloud information.

9 in total

1. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Authors: Caroline Robert; Luc Thomas; Igor Bondarenko; Steven O'Day; Jeffrey Weber; Claus Garbe; Celeste Lebbe; Jean-François Baurain; Alessandro Testori; Jean-Jacques Grob; Neville Davidson; Jon Richards; Michele Maio; Axel Hauschild; Wilson H Miller; Pere Gascon; Michal Lotem; Kaan Harmankaya; Ramy Ibrahim; Stephen Francis; Tai-Tsang Chen; Rachel Humphrey; Axel Hoos; Jedd D Wolchok
Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245

2. Improved survival with ipilimumab in patients with metastatic melanoma.

Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245

3. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Authors: Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer
Journal: N Engl J Med Date: 2010-07-29 Impact factor: 91.245

Review 4. Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy.

Authors: Emmanuel S Antonarakis; Charles G Drake
Journal: Curr Opin Oncol Date: 2012-05 Impact factor: 3.645

5. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors: Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal: J Clin Oncol Date: 2010-06-01 Impact factor: 44.544

6. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

Authors: Alfons J M van den Eertwegh; Jurjen Versluis; H Pieter van den Berg; Saskia J A M Santegoets; R Jeroen A van Moorselaar; Tim M van der Sluis; Helen E Gall; Thomas C Harding; Karin Jooss; Israel Lowy; Herbert M Pinedo; Rik J Scheper; Anita G M Stam; B Mary E von Blomberg; Tanja D de Gruijl; Kristen Hege; Natalie Sacks; Winald R Gerritsen
Journal: Lancet Oncol Date: 2012-02-10 Impact factor: 41.316

7. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

Authors: Ravi A Madan; Mahsa Mohebtash; Philip M Arlen; Matteo Vergati; Myrna Rauckhorst; Seth M Steinberg; Kwong Y Tsang; Diane J Poole; Howard L Parnes; John J Wright; William L Dahut; Jeffrey Schlom; James L Gulley
Journal: Lancet Oncol Date: 2012-02-10 Impact factor: 41.316

8. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.

Authors: Eric J Small; N Simon Tchekmedyian; Brian I Rini; Lawrence Fong; Israel Lowy; James P Allison
Journal: Clin Cancer Res Date: 2007-03-15 Impact factor: 12.531

9. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

Authors: Philip W Kantoff; Thomas J Schuetz; Brent A Blumenstein; L Michael Glode; David L Bilhartz; Michael Wyand; Kelledy Manson; Dennis L Panicali; Reiner Laus; Jeffrey Schlom; William L Dahut; Philip M Arlen; James L Gulley; Wayne R Godfrey
Journal: J Clin Oncol Date: 2010-01-25 Impact factor: 44.544

9 in total

7 in total

Review 1. The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer.

Authors: Vladimir Mouraviev; Neil Mariados; David Albala; Raoul S Concepcion; Neal D Shore; Robert B Sims; Mark Emberton; Christopher M Pieczonka
Journal: Rev Urol Date: 2014

Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer.

1. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

2. Improved survival with ipilimumab in patients with metastatic melanoma.

3. Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Review 4. Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy.

5. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

6. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

7. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

8. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.

9. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

Review 1. The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer.

Review 2. Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy.

Review 3. Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer.

Review 4. Oncolytic virus immunotherapy: future prospects for oncology.

5. Identification of Prostate Cancer Risk Genetics Biomarkers Based on Intergraded Bioinformatics Analysis.

6. Immunotherapy for prostate cancer enters its golden age.

7. Immunotherapy and immune evasion in prostate cancer.